{"id":"W2943259648","doi":"10.1016/s2352-3026(19)30029-8","title":"Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial","year":2019,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":93,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Agios Pharmaceuticals; European Hematology Association; Stand Up To Cancer; Entertainment Industry Foundation; Celgene; Astex Pharmaceuticals; Van Andel Research Institute; Pfizer; Amgen","keywords":"Decitabine; Medicine; Myelodysplastic syndromes; Hypomethylating agent; International Prognostic Scoring System; Azacitidine; Internal medicine; Clinical endpoint; Phases of clinical research; Clinical trial; Chronic myelomonocytic leukemia; Oncology; Bone marrow","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001033534,0.001556303,0.00234853,0.0002604806,0.0002227461,0.0008708427,0.0006305748,0.001290566,0.004332917],"category_scores_gemma":[0.0009905192,0.0004223794,0.001198401,0.0003432962,0.0008771757,0.0008323527,0.0003721637,0.003010402,0.0008904604],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007500473,"about_ca_system_score_gemma":0.0008226215,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001073713,"about_ca_topic_score_gemma":0.003280854,"domain_scores_codex":[0.9996787,0.0001561792,0.00001500006,0.0000547718,0.00002396916,0.00007139422],"domain_scores_gemma":[0.9995876,0.0001049731,0.00008105086,0.00002635666,0.00002247846,0.0001775684],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9338112,0.004298992,0.001275495,0.001265166,0.001339794,0.0001184866,0.00009577798,0.0006458405,0.008145758,0.0002296786,0.003456266,0.04531749],"study_design_scores_gemma":[0.9498581,0.04478189,0.002569676,0.00004374439,0.0003416068,0.0001076323,0.00002972907,0.0003351966,0.0005191531,0.000190203,0.001205046,0.00001796924],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9841456,0.008693282,0.000513666,0.001173018,0.0004555162,0.001229651,0.001501075,0.0001720223,0.002116158],"genre_scores_gemma":[0.9820957,0.005803132,0.001735584,0.001899458,0.000236008,0.001469349,0.002942116,0.00004064766,0.00377787],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004332917,"threshold_uncertainty_score":0.01449507,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04404335895220433,"score_gpt":0.3505637352000422,"score_spread":0.3065203762478379,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}